Article
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
Gynecologic oncology - 1 Mar 2021
Ghezelayagh Talayeh S, Pennington Kathryn P, Norquist Barbara M, Khasnavis Nithisha, Radke Marc R, Kilgore Mark R, Garcia Rochelle L, Lee Ming, Katz Ronit, Leslie Kimberly K, Risques Rosa Ana, Swisher Elizabeth M
Abstract excerpt
OBJECTIVES: Mutations in the TP53 tumor suppressor gene are common in ovarian carcinoma (OC) but their impact on outcomes is controversial. We sought to define the relationship of TP53 mutations to cancer outcomes and their interactions with co-occurrent BRCA1 or BRCA2 (BRCA) mutations, comparing three different TP53 mutation classification schemes. METHODS: We performed next generation sequencing on 393 cases of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.